Korea Arlico Pharm Co.,Ltd.
Financials
Valuation Metrics
Korea Arlico Pharm Co.,Ltd.'s Market Cap is ₩363B. At end of 2025 it was ₩655B. Ranked #1962 of 2,421 in KR market (top 81%), #1234 of 1,640 on KOSDAQ (top 75%), #209 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 36.33B KRW | KR#1,962/2,421 Sec#209/231 |
| Revenue | 195.70B KRW | KR#1,051/2,421 Sec#63/231 |
| Net Income | -2.85B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 170.67B KRW | KR#1,414/2,421 Sec#105/231 |
| Net Assets | 75.86B KRW | KR#1,619/2,421 Sec#132/231 |
| Employees | 242 | KR#947/2,421 Sec#82/231 |
| Value | ||
| P/B | 0.48x | KR#758/2,421 Sec#32/231 |
| P/S | 0.19x | KR#323/2,421 Sec#4/231 |
| FCF Yield | 18.95% | KR#335/2,421 Sec#5/231 |
| Profitability | ||
| ROE | -3.76% | KR#1,747/2,421 Sec#124/231 |
| ROA | -1.67% | KR#1,729/2,421 Sec#121/231 |
| Op. Margin | -4.10% | KR#1,833/2,421 Sec#122/231 |
| Revenue Growth | -3.04% | KR#1,686/2,421 Sec#162/231 |
| Earnings Growth | -1185.70% | KR#1,331/2,421 Sec#94/231 |
| Financial Health | ||
| Debt Ratio | 124.96% | KR#1,756/2,421 Sec#196/231 |
| Total Debt | 11.38B KRW | KR#1,577/2,421 Sec#140/231 |
| FCF | 6.88B KRW | KR#820/2,421 Sec#52/231 |
| Cash | 18.46B KRW | KR#1,290/2,421 Sec#97/231 |
| Current Ratio | 1.03x | KR#1,686/2,421 Sec#170/231 |
| Dividend | ||
| Div. Yield | 3.15% | KR#607/2,421 Sec#25/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -45.64% | KR#1,954/2,421 Sec#169/231 |
| 1M Return | -4.82% | KR#1,782/2,421 Sec#142/231 |
| From 52W High | -58.85% | KR#1,816/2,421 Sec#137/231 |
| 1Y MDD | -56.83% | KR#1,304/2,421 Sec#106/231 |
| Trading | ||
| Volume | 37,758 shares | KR#1,266/2,421 Sec#126/231 |
| Trading Value | 90.6M KRW | KR#1,602/2,421 Sec#158/231 |
| Foreign Own. | 4.34% | KR#975/2,421 Sec#88/231 |
| Per Share | ||
| EPS | -186 KRW | KR—/2,421 Sec—/231 |
| BPS | 4,950 KRW | KR#1,503/2,421 Sec#107/231 |
Company Info
Alico Pharmaceutical, established in 1992, manufactures and sells pharmaceuticals, having been listed on the KOSDAQ market in 2018. Its core businesses encompass domestic pharmaceutical sales, contract manufacturing organization (CMO), export of pharmaceuticals and goods, and the development and sale of medical devices, health functional foods, and cosmetics. The company has achieved external growth and profitability by focusing on profitable specialized pharmaceutical renewals, efficient production systems, and a low-cost, high-efficiency sales network. Alico Pharmaceutical is headquartered in Seocho-gu, Seoul.